FDA Approves Adjuvant Dabrafenib/Trametinib for BRAF+ Melanoma

April 30, 2018 – The FDA has approved the combination of dabrafenib and trametinib for the adjuvant treatment of patients with BRAF V600E- or V600K-positive stage III melanoma following complete resection. The approval is based on findings from the phase III COMBI-AD study, in which adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with BRAF-mutant stage III melanoma. After a median … (leggi tutto)